MRNA is still up 6% with volume now above its ADV
bigcharts.marketwatch.com
It announced today that the U.S. Patent Office has issued a Notice of Allowance for its patent application covering an siRNA directed against a junctional adhesion molecule-1 gene.
According to the company,the allowed claim has a broad array of potential applications, as a therapeutic approach for certain cancers, thrombosis, atherosclerosis, strokes, and hypertension; and it enhances the delivery of drugs across the skin and the blood-brain barrier.
JAM-1 is reportedly a tight junction protein that plays a key role in maintaining epithelial and endothelial barrier functions, leukocyte transmigration and platelet adhesion and also functions as a pro-inflammatory molecule.
The CEO said: "This allowance validates our patent strategy for our gene target portfolio, and reinforces our belief that we will obtain patent protection for our extensive library of siRNAs directed against more than 140 therapeutic gene targets."
As prviously mentioned, MRNA has been trimming its losses and as was also mentioned, on April 2, it announced that it had sold its Manufacturing Business to Par Pharmaceuticals and it was concentrating on its RNAi projects. According to its CEO, Michael French, "that agreement eliminates all of MDRNA's non-RNAi expenses and represents the final step in the plan to create a company solely focused in the research and development of RNAi-based therapeutics."
It is expected that MRNA reports on the two pending Qs will look good compared to 2008, and the 'target' remains unchanged.<g>
bigcharts.marketwatch.com
Bernard
|
